hu2B6-3.5 exert in vivo antitumor activity against B-lymphoma xenografts. (A) Daudi cells (5 × 106/mouse) in Matrigel were injected subcutaneously into the right flank of 8- to 11-week-old BALB/c nude female mice (N = number of mice per group). Intraperitoneal injections of antibodies hu2B6-3.5 (top panels) or rituximab (bottom panels) at the indicated total mouse doses were performed weekly for 8 weeks, starting at day 0. Mean tumor volumes are plotted and error bars represent the SE of measurement (left panels). Tumor-free survival was plotted using the Kaplan-Meier method (right panels) and analyzed for significance (*P < .001) using the log-rank test. (B) The experiment was conducted as in panel A except that Daudi cells (5 × 106/mouse) were allowed to establish for 7 days prior to treatment with 4 consecutive daily intraperitoneal injections of PBS or the indicated antibodies (100 μg/mouse, N = 6).
